MOTS-c
Restore cellular fuel efficiency.
SC injection; IV infusion — 5–10 mg SC injection 2–3x per week; 5–10 mg IV in STABILIS and CORE GENESIS formulas; start with lower doses (5 mg) and monitor symptoms
What It Is
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA. It acts as an exercise mimetic and metabolic regulator, targeting skeletal muscle to enhance insulin sensitivity and fat oxidation.
Mechanism
MOTS-c activates AMPK via the folate-purine pathway to enhance insulin sensitivity and fat oxidation. In mice, MOTS-c prevented diet-induced obesity and age-related insulin resistance, essentially protecting against metabolic slowdowns of aging. This "mitochondrial signal" peptide links exercise and longevity: human studies show exercise naturally raises MOTS-c levels, and giving MOTS-c improves physical performance across young and old animals. It activates AMPK and improves insulin sensitivity and metabolic homeostasis — making cells behave as if they're exercising.
How Dr. Emer Uses It
Emer's RECODEX stacks include MOTS-c in RE:STORE™ phases to "restore cellular fuel efficiency," often pairing it with NAD+ for synergistic mitochondrial rejuvenation. Given 5–10 mg SC injection 2–3x per week (e.g. Monday/Friday) for 4–6 weeks. It is used clinically for fat loss, metabolic syndrome, and fatigue — especially useful for patients over 40 whose mitochondrial output is declining. In the STABILIS IV it appears at 5–10 mg IV to ensure ATP resilience during healing. In the CORE GENESIS IV, 10 mg IV is included as a mitochondrial peptide that upregulates AMPK.
Key Benefits
- ✓Activates AMPK via the folate-purine pathway for enhanced metabolic function
- ✓Improves insulin sensitivity and reduces age-related insulin resistance
- ✓Acts as an exercise mimetic — raises fat oxidation without physical training
- ✓Increases energy and exercise tolerance (described by some as an endurance booster)
- ✓Prevents diet-induced obesity and metabolic slowdown in aging
- ✓Reduces inflammatory cytokines, beneficial for autoimmune and metabolic conditions
Pairs Well With
Used In Programs
Safety & Considerations
As an experimental peptide, it is well-tolerated in short studies (one-week dosing showed no serious adverse events). However, anecdotal user reports mention temporary fatigue, mild insomnia, or heart palpitations during MOTS-c cycles. These are transient and dose-dependent. EmerGPT advises starting with lower doses (5–10 mg 2–3x weekly) and monitoring symptoms. No long-term human safety data exists. Investigational; derived from mtDNA; no known acute issues. Avoid in pregnancy (unknown effects).
Begin Your RECODEX™ Protocol
All peptide therapies are prescribed under direct medical supervision.
Book a Consultation
